Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
197 studies found for:    hepatitis c phase 2 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
Condition: Hepatitis C Virus
Intervention:
2 Recruiting A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Conditions: Hepatitis C Viral Infection;   Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 1
Interventions: Drug: Faldaprevir;   Drug: TD-6450;   Drug: Ribavirin
3 Recruiting A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: TG-2349;   Drug: Ribavirin;   Drug: Interferon Alfa-2a
4 Recruiting A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use
Condition: Hepatitis C
Intervention: Drug: Sofosbuvir (SOF)/GS-5816
5 Unknown  CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
Condition: Chronic Hepatitis C
Interventions: Drug: ChronVac-C + SOC;   Drug: SOC
6 Unknown  Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
Conditions: Hepatitis C;   Hepatitis B
Intervention: Drug: Pegasys; Copegus.
7 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: Placebo
8 Not yet recruiting Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: AL-335;   Drug: Odalasvir;   Drug: Simeprevir
9 Unknown  A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
Condition: Chronic Hepatitis C
Interventions: Drug: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets);   Drug: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection;   Drug: Rebetol® (ribavirin), 1000/1200mg by mouth daily
10 Recruiting A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir
Condition: Chronic Hepatitis C
Interventions: Drug: AL-335;   Drug: ACH-3102;   Drug: Simeprevir
11 Unknown  A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Celgosivir;   Drug: Peginterferon alfa 2b + ribavirin
12 Recruiting Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF (oral tablets);   Drug: RBV;   Drug: SOF (oral granules)
13 Recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
14 Recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: Placebo to match LDV/SOF;   Drug: RBV
15 Unknown  Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
Condition: Hepatitis C
Intervention: Drug: thalidomide
16 Recruiting Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas
Conditions: Indolent B-cell Lymphoma;   Hepatitis C
Interventions: Drug: Sofosbuvir+Ledipasvir;   Drug: Sofosbuvir+Ribavirin;   Drug: Sofosbuvir+Ledipasvir+Ribavirin
17 Recruiting Efficacy and Safety of MK-3682 With MK-8408 in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Condition: Hepatitis C, Chronic
Interventions: Drug: MK-3682 450 mg;   Drug: MK-8408 60 mg
18 Unknown  Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
Conditions: Hepatitis C, Chronic;   Liver Diseases;   Interferon Deficiency
Intervention: Drug: interferon alpha 2b
19 Recruiting 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Conditions: HIV-1 Infection;   Hepatitis C
Interventions: Drug: Ledipasvir/sofosbuvir;   Drug: Ribavirin
20 Recruiting Liver Test Study of Using JKB-122 in HCV-Positive Patients
Condition: Chronic Hepatitis C
Interventions: Drug: JKB-122;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years